You just read:

Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

News provided by

Quark Pharmaceuticals, Inc. , Biocon Ltd.

Jun 23, 2016, 00:01 ET